Representation of Ayala Pharmaceuticals in an Initial Public Offering (IPO)
Our firm represented Ayala Pharmaceuticals, a clinical-stage oncology company that develops small molecule therapeutics for rare and aggressive cancers, in an initial public offering on Nasdaq, raising $55 million, 10% more than planned. For more info click here.